Why knee cartilage cannot repair itself

Knee cartilage does not heal the way a cut or a broken bone does — and the reason is structural, not incidental. Articular cartilage has no blood supply of its own; it depends entirely on slow nutrient diffusion from the surrounding synovial fluid. Because no blood reaches it, the inflammatory repair cascade — the platelets, white cells, and growth factors that mend other tissues — never arrives at a chondral defect. The injury simply sits there.

This is not a rare predicament. Registry studies spanning thousands of knees — including a review of 31,516 knee arthroscopies by Curl et al. and a series of 993 consecutive procedures by Aroen et al. — found cartilage lesions in the majority of joints examined, many of which were clinically silent until symptoms escalated.

Causes range from a single acute injury to repetitive loading, prior ligament or meniscal damage, and the gradual wear of ageing. Left unaddressed, a focal chondral defect exposes the underlying subchondral bone to direct compressive stress, accelerating the joint's progression toward osteoarthritis. That biological dead-end — an avascular tissue that cannot self-repair, in a joint that carries the body's full weight — is the reason active intervention matters for eligible patients.

The ultrasound-guided collagen scaffold injection

For eligible patients, the entire procedure takes place in an outpatient clinic — no general anaesthetic, no theatre admission, and no incisions. Under ultrasound imaging, a clinician injects ChondroFiller® liquid, a CE-marked Class III acellular Type I collagen scaffold, directly into the affected compartment of the knee. The appointment is broadly comparable in experience to a guided steroid or hyaluronic acid injection, though the material delivered — and what it does inside the joint — is distinct.

Once placed, the collagen scaffold cross-links into a stable hydrogel within roughly one to five minutes. This temporary matrix then acts as a structural framework, drawing the patient's own progenitor cells from the surrounding synovium and subchondral bone into the defect — a process described as acellular matrix-induced chondrogenesis. There is no cell-expansion laboratory stage, no two-stage procedure, and no waiting weeks between appointments. A single outpatient visit completes the treatment.

Because the scaffold is delivered by injection rather than surgically implanted, there is no mandatory crutch-dependent recovery protocol. Patients are not required to be non-weight-bearing for the weeks that follow arthroscopic marrow-stimulation surgery.

ChondroFiller® is indicated for focal cartilage defects up to 6 cm², which means it is potentially suitable for defects considered too large for marrow stimulation — widening the pool of patients who may avoid a surgical pathway altogether. There is no upper age limit associated with the injection route, and Kellgren–Lawrence Grade III/IV knees are not automatically excluded.

Microfracture surgery and its core limitation

Microfracture has genuine strengths: it is arthroscopically delivered, widely available, requires no cell-expansion laboratory stage, and has accumulated decades of clinical use globally. The procedure works by using a small awl to create multiple perforations in the subchondral bone beneath the cartilage defect. This triggers a marrow-derived clot — the so-called super-clot — from which repair tissue gradually matures.

The limitation lies in the nature of that repair tissue. Rather than native hyaline cartilage (Type II collagen), microfracture consistently produces fibrocartilage (Type I collagen). This is not a matter of surgical technique; it reflects a fundamental microenvironmental constraint. The marrow cells released by the procedure lack the biochemical cues needed to commit fully to chondrogenic differentiation, so the tissue they form has a different structure and wears differently under load.

This ceiling shows clearly in long-term imaging data. A five-year prospective RCT recorded a mean MOCART score of just 26.7 for microfracture — compared with 62.3 for cell-based implantation (p<0.0001). The procedure also carries a reoperation rate of up to 41% in comparative analyses. Post-operatively, patients typically require crutches for up to six weeks, a substantial functional burden.

Microfracture also has a recognised defect-size threshold: outcomes are generally more predictable for lesions below 2–4 cm², with larger defects less well served. In older patients, the picture narrows further — age-related decline in bone marrow stromal cell stemness is directly associated with poorer repair outcomes, limiting the procedure's applicability in the demographic most likely to present with degenerative chondral lesions.

How the clinical outcomes compare

Before comparing figures, the evidence base deserves an upfront note. Published ChondroFiller® knee cohorts are small — typically 8–30 patients — and most originate from manufacturer-sponsored clinical evaluation programmes. No head-to-head randomised controlled trial against microfracture yet exists. This is not a disqualifying position; it reflects a technology that is actively building its evidence base rather than one with the decades-long trial accumulation behind established surgical procedures. Holding that context, the functional data are as follows.

Across four knee cohort studies, IKDC scores — a validated composite measure of knee function and symptoms — improve by approximately 30 points at 12 months following ChondroFiller® injection. That comfortably exceeds the 16.7-point minimum clinically important difference: the threshold below which an improvement is unlikely to be meaningfully felt by the patient in daily life. The Jerosch et al. prospective PMCF study recorded a mean gain of 32.4 points, sustained and slightly increased at three years, with patients reaching a functional score of 80.

MRI-based MOCART scores quantify how completely repair tissue fills the defect and integrates with the surrounding cartilage; a score above 80 generally indicates good structural fill. ChondroFiller® cohorts consistently record MOCART values of 81.6–84.3. By comparison, microfracture returned a mean MOCART of 26.7 in a five-year prospective RCT — a gap that reflects the tissue-quality difference discussed in the previous section.

Reoperation rates follow a similar pattern: approximately 3–8% for ChondroFiller® versus up to 41% for microfracture in available comparative data, suggesting meaningfully different long-term durability, though direct equivalence trials are still needed to confirm that relationship.

Which patients are suited to the injection pathway

The clearest differentiator from microfracture is access: the ChondroFiller® injection pathway carries neither an upper age ceiling nor a defect-size floor below the 6 cm² treatment limit, making it available to patients routinely excluded from marrow-stimulation procedures.

Patients with Kellgren-Lawrence Grade III or IV knee changes — a level of degenerative change that typically disqualifies candidates from microfracture surgery — can be considered for the injection pathway. The collagen scaffold acts as a mechanical cushion placed over worn articular surfaces, a function that does not depend on the clean subchondral bed preparation that marrow stimulation requires.

Because no general anaesthetic is involved, surgical fitness is not a barrier in the same way as for theatre-based procedures — an important consideration for older patients or those with cardiovascular or respiratory comorbidities.

Two eligibility filters do apply and should be stated plainly. First, the pathway is available privately in the UK; NHS funding is not currently in place, and cost is a genuine practical constraint for many patients. Second, individual suitability requires clinical assessment. Where joint degeneration is sufficiently advanced that too little articular surface remains, the injection approach is unlikely to be appropriate and the conversation typically shifts toward joint replacement planning. The boundary between these categories is not always apparent from history alone, which is why imaging review forms part of any initial assessment of suitability.

Getting an assessment at Lincolnshire Knee

The evidence reviewed here does not position the ultrasound-guided collagen scaffold injection as a universal answer to focal cartilage damage — but it does establish a credible alternative for the patients microfracture serves least well: older adults, larger defects, and those with established degenerative change alongside a focal lesion. The tissue-quality gap between fibrocartilage and hyaline-like repair, the diverging MOCART trajectories at five years, and the reoperation differential all point in the same direction. For eligible patients, the injection pathway offers meaningful functional gains without the recovery burden or biological constraints of marrow stimulation.

The practical next step is an accurate picture of the defect — its size, location, and the condition of the surrounding cartilage. At Lincolnshire Knee, consultant-led assessments are available without GP referral at sites in Sleaford (NG34) and Grantham (NG31); where imaging review is indicated, AI-assisted MRI cartilage analysis (onMRI™) can help characterise lesion extent before any treatment decision is made. To arrange an assessment, visit lincolnshireknee.co.uk.

1. [1] Hand-minced cartilage versus microfracture for the repair of articular cartilage defects: A propensity score matched-pair analysis with 2-year follow-up. (2025). https://doi.org/10.1002/ksa.12728 https://doi.org/10.1002/ksa.12728